{"organizations": [], "uuid": "8ca737cc4981815a16442a5040e85cac70449c94", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ema-recommends-immediate-suspensio/brief-ema-recommends-immediate-suspension-recall-of-multiple-sclerosis-medicine-zinbryta-idUSFWN1QP07K", "country": "US", "domain_rank": 408, "title": "BRIEF-EMA Recommends Immediate Suspension, Recall Of Multiple Sclerosis Medicine Zinbryta", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-07T12:09:00.000+02:00", "replies_count": 0, "uuid": "8ca737cc4981815a16442a5040e85cac70449c94"}, "author": "", "url": "https://www.reuters.com/article/brief-ema-recommends-immediate-suspensio/brief-ema-recommends-immediate-suspension-recall-of-multiple-sclerosis-medicine-zinbryta-idUSFWN1QP07K", "ord_in_thread": 0, "title": "BRIEF-EMA Recommends Immediate Suspension, Recall Of Multiple Sclerosis Medicine Zinbryta", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "eu medicines agency", "sentiment": "none"}, {"name": "multiple sclerosis medicine zinbryta reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7, 2018 / 10:09 AM / Updated 30 minutes ago BRIEF-EMA Recommends Immediate Suspension, Recall Of Multiple Sclerosis Medicine Zinbryta Reuters Staff March 7 (Reuters) - EU Medicines Agency: * EMA RECOMMENDS IMMEDIATE SUSPENSION AND RECALL OF MULTIPLE SCLEROSIS MEDICINE ZINBRYTA * EMA RECOMMENDATION FOLLOWING 12 REPORTS OF SERIOUS INFLAMMATORY BRAIN DISORDERS WORLDWIDE, INCLUDING ENCEPHALITIS AND MENINGOENCEPHALITIS * EMA’S RECOMMENDATION TO SUSPEND ZINBRYTA AND RECALL THE PRODUCT IS BEING SENT TO THE EUROPEAN COMMISSION FOR A LEGALLY BINDING DECISION * PRELIMINARY REVIEW OF EVIDENCE INDICATES IMMUNE REACTIONS OBSERVED IN REPORTED CASES MAY BE LINKED TO USE OF ZINBRYTA‍​ Source text ID: ( bit.ly/2oWAUEF ) Further company coverage:", "external_links": [], "published": "2018-03-07T12:09:00.000+02:00", "crawled": "2018-03-07T12:50:49.001+02:00", "highlightTitle": ""}